CSPC Pharmaceutical Group Ltd (CHJTF)

CSPC Pharmaceutical Group Ltd is a listed common stock of an investment holding company focused on pharmaceutical manufacturing and sales. The group operates in Mainland China as well as other Asian markets, Europe, North America, and other international regions. Its activities are organized across Finished Drugs, Bulk Products, and Functional Food and Others segments. The company’s portfolio includes treatments for stroke, memory impairment, Parkinson’s disease, several cancers, infections, hypertension, thrombosis prevention, diabetes, osteoporosis, pain, ulcers, and inflammatory conditions. CSPC also supplies active pharmaceutical ingredients such as antibiotics, vitamin C, and caffeine, along with functional food products and healthcare services. Incorporated in 1992 and headquartered in Shijiazhuang, the People’s Republic of China, the company was formerly known as China Pharmaceutical Group Limited and adopted its current name in 2013. It also has a strategic collaboration with AstraZeneca PLC to support research and development of novel oral candidates for obesity and type 2 diabetes, among other potential indications.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.